Jan 17, 2019
Lose Your Weight Very Fast. Yoga For Obesity.
seen from United States
seen from United States
seen from China
seen from Czechia
seen from Russia
seen from China
seen from Sweden
seen from Netherlands
seen from United States
seen from Slovakia
seen from Canada
seen from United States
seen from United States
seen from Canada
seen from Bulgaria
seen from Türkiye
seen from Slovakia
seen from Russia
seen from United States
seen from Netherlands
Lose Your Weight Very Fast. Yoga For Obesity.
Eat less. But the usual means of weight loss people try — starving themselves or going on fad diets — simply do not work. Losing weight doesn't mean going hungry; it means eating well.
Scientists at the University of Ohio have found out the risks that affect obesity
A hundred people aged 20-78 years were participants in the study, half of whom were obese (mean index of body mass index was 36.8).
Scientists are interested in how the obesity can be influenced by psychological features, the situation prevailing in the house, and even the architecture of the building.
More products were stored in the visibility zone in those who suffered from obesity. In addition, they used foods that have less benefit to the body: sweets, flour, etc.
The number of products for all volunteers was almost the same. In obese people, food was not only in the kitchen, but also in a number of places.
Researchers have found a number of psychological features in participants with obesity. For example, their self-esteem, which was related to weight, was much lower than those who did not have obesity. Obese people also had obvious symptoms of depression.
That is, in order that you do not have obesity, you need to keep fewer products in sight, so that there is no temptation to eat again.
Obesity: causes, prevention and ways to get rid of excess weight.
Overweight and obesity is an excessive increase in the body weight of a person due to fat mass, which can harm the health.
The presence of excess weight is not just an aesthetic drawback. A type II diabetes mellitus, cardiovascular diseases, joint diseases, varicose veins will develop more likely in a person with an excess of kilograms than with normal body weight. Large excess weight reduces the reproductive potential of both women and men, and can lead to infertility.
Benfits of Weight Loss in Women With HIV
New Post has been published on http://type2diabetestreatment.net/obesity-help/benfits-of-weight-loss-in-women-with-hiv/
Benfits of Weight Loss in Women With HIV
March 31, 2017 Benfits of Weight Loss in Women With HIV This article originally appeared here. Share this content:
Moderate, diet-induced weight loss can improve metabolic and cardiovascular risk factors in women with HIV.
A clinical trial comparing the effects of weight loss on HIV-infected (HIV+) and HIV-uninfected (HIV−) women with obesity found that both groups derived similar metabolic benefits, according to results published in Obesity.1
In an email interview with Infectious Disease Advisor, Jeffrey A. Lederman, MD, chief of infectious diseases at Montefiore Medical Center, New Rochelle, New York, noted that due to currently available antiretroviral therapies, patients with HIV are living normal lives, which includes the potential for weight gain. “Many patients who had been wasting away before starting medications are now developing obesity. I've had to advise them that previously their weight may have been low due to the infection. However, once the infection is well controlled, the patient may have to carefully diet to keep from becoming overweight.” Dr Lederman was not involved in the clinical trial.
Continue Reading Below
The metabolic risks of obesity are of special clinical concern in the HIV+ population. HIV+ individuals have a risk for type-2 diabetes and cardiovascular disease (CVD) that is 2 to 4 times greater than that in HIV−individuals with the same BMI. Weight loss in the general population is known to improve metabolic function, but few prior studies examined whether weight loss is beneficial in a similar manner in patients living with HIV. Lead investigator Dominic N. Reeds, MD of the Washington University School of Medicine, St Louis, Missouri, and colleagues hypothesized that compared with HIV− women, HIV+ women would experience fewer improvements in insulin sensitivity and markers of inflammation, autophagy, and endoplasmic reticulum (ER) stress with weight loss.
For the study, 8 HIV+ and 20 HIV− women with obesity and confirmed insulin resistance took part in a weight loss regimen involving liquid meal replacements for 2 meals per day and weekly counseling from a research dietitian. The meal plan, designed to result in a 1000 kcal/d energy deficit, was continued until patients individually reached a 6% to 8% weight loss. That goal was achieved in 19 of the 28 participants (13 HIV+ and 6 HIV−).
The researchers assessed the participants' body composition, blood pressure, and metabolic parameters before and after the weight loss intervention. In order to measure the women's plasma glucose concentration, plasma palmitate, glucose tracer-to-tracee ratios, and plasma hormone concentrations, patients underwent a hyperinsulinemic-euglycemic clamp procedure, a technique that represents the gold standard for quantifying the impact of experimental interventions on insulin sensitivity.2 Body fat and fat-free mass were quantified with dual-energy X-ray absorptiometry, and magnetic resonance imaging (MRI) was used to determine visceral and abdominal subcutaneous adipose tissue volumes.
Results showed a weight loss of approximately 7.5% in both groups. HIV+ patients had a greater decrease in fat-free mass after weight loss (-4.4±0.7% difference, P <.05) than HIV- patients (-1.7±1.0% difference, P <.05). Both HIV+ and HIV− women saw similar improvements in insulin sensitivity in adipose tissue (suppression of palmitate rate of appearance [Ra]), liver (suppression of glucose Ra), and muscle (glucose disposal). Systolic and diastolic blood pressure improved in both HIV+ and HIV− patients. Adipose tissue expression of markers of inflammation, autophagy, and ER stress remained unchanged in both groups.
“These results demonstrate that moderate diet-induced weight loss has important therapeutic cardiometabolic effects in HIV-1 women with obesity,” the investigators wrote. “In summary, moderate weight loss improved multiorgan insulin sensitivity and several other key risk factors for CVD in women with obesity and HIV infection to the same degree that weight loss improved these outcome measures in women with obesity but without HIV infection.”
Related Articles
Obesity Paradox Reported in Atrial Fibrillation Outcomes
Elevated Hair Cortisol Concentration Associated with Adiposity, Obesity Persistence
Do People With Obesity Always Present With Cardiometabolic Risk Factors?
References
Reeds DN, Pietka TA, Yarasheski KE, et al. HIV infection does not prevent the metabolic benefits of diet-induced weight loss in women with obesity [published online February 28, 2017]. Obesity. doi:10.1002/oby.21793
Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining Insulin Resistance From Hyperinsulinemic-Euglycemic Clamps. Diabetes Care. 2012;35:1605-1610. doi:10.2337/dc11-2339
Related Topics
Metabolic Syndrome
Nutrition
Obesity
Endocrinology Advisor Articles
Hypovitaminosis D Associated With High 24-Hour Ambulatory BP in Type 2 Diabetes
Recommended Dietary Allowance of Vitamin D3 Lower Than IOM Suggestion
Obesity Paradox Reported in Atrial Fibrillation Outcomes
The Handoff: Your Week in Endocrinology News - 4/7/17
Higher Thyroid-Stimulating Hormone Levels Associated With Worse Heart Failure
Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in Type 2 Diabetes
Significant Fracture Burden, Psychological Comorbidities Associated With Hypophosphatasia
Oral Levothyroxine Absorption Reduced By Cow's Milk Consumption
Limited Association Between Depression and Vitamin D Deficiency
Testosterone Therapy Increases Live Birth Rates in IVF
How Does Antenatal Betamethasone Exposure Affect Pediatric Bone Mass?
Timing of Cognitive Decline Linked to Insulin Resistance
Is Normal Basal Bone Metabolism Vitamin D-Dependent in Postmenopausal Women With T2D?
Anti-fracture Therapy Effectively Prevents Bone Loss in Women Post-Critical Illness
Hypertension Family History May Accelerate Type 2 Diabetes Onset
Sign Up for Free e-Newsletters
Diabetes Type II Treatment 800 Calorie Diabetic Diet Diabetes Solution Original Article
Increased Risk of Metabolic Syndrome in Women on Inhaled Corticosteroids
New Post has been published on http://type2diabetestreatment.net/obesity-help/increased-risk-of-metabolic-syndrome-in-women-on-inhaled-corticosteroids/
Increased Risk of Metabolic Syndrome in Women on Inhaled Corticosteroids
April 07, 2017 Increased Risk of Metabolic Syndrome in Women on Inhaled Corticosteroids This article originally appeared here. Share this content:
Data from a study of 140,879 adults was analyzed to evaluate associations between corticosteroids and metabolic syndrome
Findings from a large study, presented at ENDO 2017, April 1-4, 2017, in Orlando, Florida. showed that inhaled corticosteroid (ICS) use by women may raise their risk of developing metabolic syndrome and was associated with higher body mass index (BMI).
ICS are common anti-inflammatory agents used to treat asthma and other respiratory diseases. According to study author Mesut Savas, MD, MSc, at Erasmus MC, Rotterdam, Netherlands, the adverse events associated with corticosteroids primarily occur with the use of systemic types and less in the locally applied forms of corticosteroids.
However, the study's lead author Elisabeth van Rossum, MD, PhD, added that ICS may exert "greater systemic effects than recognized."
Continue Reading Below
Metabolic syndrome consists of having ≥3 risk factors: increased waistline, increased blood pressure, increased levels of fasting blood sugar, and/or triglycerides, and decreased levels of HDL.
Using data from the Lifelines Study Cohort of 140,879 Dutch adults, the study found that more than 1 in 10 people were using corticosteroids. Study patients were given a questionnaire about drug use and they were evaluated for features of metabolic syndrome.
Of the 15,328 who used corticosteroids, 14,621 used topical forms such as creams, eye drops, nose sprays, and inhalers. Moreover, >50% (n=7,719) of these patients used inhaled types alone or in combination with other corticosteroids.
Patients who used corticosteroids had a 1.1-fold increased risk of having metabolic syndrome vs. corticosteroid non-users. The likelihood was more pronounced in women vs. men with a 1.2-fold higher risk among women who used any corticosteroid.
Specifically, the use of ICS correlated to a 1.4-fold increased risk of having metabolic syndrome in women.
With regards to BMI, corticosteroid users had a higher average BMI vs. non-users (difference 0.31kg/m2) with an even higher BMI increase among ICS users (0.65kg/m2). Compared to women who were corticosteroid non-users, women using ICS had a 0.86kg/m2 higher BMI.
“This could warrant stricter monitoring of these adverse effects and potentially more restraint in prescriptions of this type of medication, especially in women at risk of the metabolic syndrome,” said Dr. Rossum.
The researchers concluded by saying that while the findings suggest an association, they do not prove causality, and warrant more research.
Reference
Savas M Associations between local corticosteroid use, metabolic syndrome, and body mass index in a large population-based cohort study: The Lifelines Cohort Study. Abstract OR03-02. Presented at: ENDO 2017: the 99th Annual Meeting & Expo. April 1-4, 2017; Orlando, Florida.
Associations Between Local Corticosteroid Use, Metabolic Syndrome, and Body Mass Index in a Large Population-Based Cohort Study: The Lifelines Cohort Study Associations Between Local Corticosteroid Use, Metabolic Syndrome, and Body Mass Index in a Large Population-Based Cohort Study: The Lifelines Cohort Study Associations Between Local Corticosteroid Use, Metabolic Syndrome, and Body Mass Index in a Large Population-Based Cohort Study: The Lifelines Cohort Study
Endocrinology Advisor Articles
Oral Levothyroxine Absorption Reduced By Cow's Milk Consumption
Long-Term Androgen Therapy Increases Cardiovascular Risk in Transgender Men
Does Metformin Therapy During Pregnancy Affect Metabolic Health in PCOS?
Systemic Anti-inflammatory Effects of Linagliptin in Type 2 Diabetes
Empagliflozin Use Supported in Patients With DM Post-Cardiac Transplantation
Do Gluten-Free Diets Elevate Type 2 Diabetes Risk?
Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in Type 2 Diabetes
Significant Fracture Burden, Psychological Comorbidities Associated With Hypophosphatasia
Oral Levothyroxine Absorption Reduced By Cow's Milk Consumption
Limited Association Between Depression and Vitamin D Deficiency
Hypovitaminosis D Associated With High 24-Hour Ambulatory BP in Type 2 Diabetes
Obesity Paradox Reported in Atrial Fibrillation Outcomes
Analyzing Trends and Recent Controversies in Cardiovascular Nutrition
Increased Risk of Metabolic Syndrome in Women on Inhaled Corticosteroids
Thyroid Dysfunction in Children May Affect Cognitive Skills
Sign Up for Free e-Newsletters
Diabetes Type II Treatment 800 Calorie Diabetic Diet Diabetes Solution Original Article
Intravisceral Abdominal Fat Mass Reduction With Menopausal Hormone Therapy
New Post has been published on http://type2diabetestreatment.net/obesity-help/intravisceral-abdominal-fat-mass-reduction-with-menopausal-hormone-therapy/
Intravisceral Abdominal Fat Mass Reduction With Menopausal Hormone Therapy
Lauren Biscaldi, Assistant Editor March 27, 2017 Intravisceral Abdominal Fat Mass Reduction With Menopausal Hormone Therapy Share this content:
Researchers examined body mass index differences in current, past, and never users of menopausal hormone therapy.
Long-term cessation of menopausal hormone therapy (MHT) does not preserve the level of fat mass reduction experienced by current MHT users, according to research presented at the 2017 World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, that took place March 23-26 in Florence, Italy.
Researchers at Lausanne University Hospital in Switzerland conducted a cross-sectional, population-based study using data from 1500 women enrolled in the OsteoLaus cohort study to determine the correlation between MHT and changes to fat and lean tissue.
Continue Reading Below
OsteoLaus is a cohort of women 50 to 80 years of age living in Lausanne, Switzerland with clinical risk factors for osteoporosis who were regularly evaluated for osteoporosis progression.
Study investigators assessed participants' current or past MHT use via questionnaire. Body composition was evaluated using dual-energy X-ray absorptiometry (DXA) in a subgroup of 1094 participants. The remaining 972 participants were divided into 3 groups as follows:
n Age (SD) Body Mass Index (SD) Never Users (NU) 505 61 (7.8) 25.2 (4.1) kg/m2 Current Users (CU) 205 62.5 (6.7) 25.9 (4.5) kg/m2 Past Users* (PU) 262 66.6 (6.2) 26.1 (4.2) kg/m2
*Among PU, average time since MHT withdrawal was 8.4 years
Results across all groups were age-adjusted. Total fat mass was lowest in the CU group and highest in the PU group (P =.05); trunk fat mass was 10.35±4.05, 10.83±4.35, and 11.35±4.14 kg in the CU, NU, and PU groups, respectively (P = .04).
No difference in gynoid fat mass was noted, but a “marked decrease” of intravisceral fat was identified in the CU group compared with the NU and PU groups (P <.01).
“MHT is associated with less adiposity, due to reduction in android fat mass,” the researchers concluded.
“The significant decrease of intravisceral fat mass in CU is of particular interest, given the strong link of the latter with cardiovascular risk.”
Related Articles
Bone Health Improved With Menopausal Hormone Therapy
Clinical Trial Knowledge Tied to Prescribing of Menopausal Hormone Therapy
Compounded Hormone Use Common Among Menopausal Hormone Therapy Users
Reference
Papadakis G, Hans DH, Vollenweider P, Waeber G, Marques-Vidal P, Lamy O. Menopausal hormone therapy is associated with reduced fat mass and in particular a significant decrease of intravisceral abdominal fat: the OsteoLaus cohort. Abstract P838. Presented at: 2017 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. March 23-26, 2017; Florence, Italy.
Related Topics
Menopause
Obesity
WCO 2017
Upcoming Meetings
APRIL 1-4 • ENDO 2017 Orlando, FL
APRIL 2-4 • American Association of Endocrine Surgeons (AAES) 38th Annual Meeting Orlando, FL
APRIL 20-22 • Clinical Osteoporosis 2017 Orlando, FL
Click here to view the full calendar
Sign Up for Free e-Newsletters
Endocrinology Advisor Articles
Elevated Hair Cortisol Concentration Associated with Adiposity, Obesity Persistence
Higher Complications, Comorbidities in Youth With Type 2 Versus Type 1 Diabetes
The Handoff: Your Week in Endocrinology News - 3/24/17
Mortality In Type 2 Diabetes Increased With Severe Hypoglycemia Episode
Hepatitis B Therapy Associated With Abnormal Bone Metabolism
Do Gluten-Free Diets Elevate Type 2 Diabetes Risk?
Fitbit Pitfalls: Electronic Tracking Devices May Not Provide Increased Weight Loss Benefits
Differential Adverse Renal Effects With Dapagliflozin, Empagliflozin in Type 2 Diabetes
Preoperative Glargine Dosing May Affect Perioperative Glycemic Control
STEMI Symptom Presentation Delayed in Diabetes
Acute Kidney Injury Rate High in Hospitalized Children With Diabetic Ketoacidosis
Diabetic Retinopathy Screening Lacking Among Pediatric Patients
Diabetes Risk in Elderly Women Increased by Statin Use
On-Site Hospital Surveys Lead to Reduced Mortality
American Diabetes Association Voices Concern Over American Health Care Act
Diabetes Type II Treatment 800 Calorie Diabetic Diet Diabetes Solution Original Article